Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) announced on Tuesday that its CEO, Kelvin Cooper, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.

The company says that during the conference, Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.

Lakewood-Amedex Biotherapeutics is developing a novel class of fast-acting, broad-spectrum antimicrobials, called the Bisphosphocin class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others.